Crouse Steven C. 4
4 · BIO-TECHNE Corp · Filed Jun 4, 2026
Research Summary
AI-generated summary of this filing
Bio‑Techne (TECH) President Steven C. Crouse Exercises 600 Shares
What Happened
Steven C. Crouse, President — Diagnostic & Spatial Biology at Bio‑Techne, converted/exercised 600 restricted stock units (derivative exercise/conversion) on 2026-06-02. To satisfy tax withholding, 216 shares were surrendered/disposed at $49.77 per share, generating $10,750 in withholding. The filing also shows a related derivative disposition entry for 600 shares at $0, reflecting the conversion/exercise mechanics. Net shares delivered to Crouse from this transaction were 384 (600 acquired − 216 withheld).
Key Details
- Transaction date: 2026-06-02. Transaction codes: M = exercise/conversion of derivative; F = payment of exercise price or tax liability (withholding).
- Withholding: 216 shares withheld at $49.77/share = $10,750.
- Gross shares converted: 600 RSUs; net shares received: 384.
- Notable footnotes: F1 clarifies each restricted stock unit equals one common share; F3 indicates 600 RSUs vest on 6/2/2026 (the vesting that triggered this conversion); F17 notes a correction to a prior Form 4 that increases beneficial ownership by 40 shares.
- Shares owned after transaction: not specified in the provided excerpt of the filing.
- Filing timeliness: no late‑filing indicator provided in the excerpt.
Context
This was a routine conversion/vesting of restricted stock units with shares withheld to cover taxes (a common cashless-like withholding). M-code transactions are exercises/conversions of derivative awards; F-code transactions reflect tax withholding. Such withholding sales are administrative and do not necessarily indicate a buy or sell signal by the insider.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1][F17]2026-06-02+600→ 6,977 total - Tax Payment
Common Stock
2026-06-02$49.77/sh−216$10,750→ 6,761 total - Exercise/Conversion
Restricted Stock Units
[F1][F3]2026-06-02−600→ 1,200 total→ Common Stock (600 underlying)
- 794
Restricted Stock Units
[F1][F2]→ Common Stock (794 underlying) - 1,379
Restricted Stock Units
[F1][F4]→ Common Stock (1,379 underlying) - 3,737
Restricted Stock Units
[F1][F5]→ Common Stock (3,737 underlying) - 6,529
Restricted Stock Units
[F1][F6]→ Common Stock (6,529 underlying) - 3,856
Stock Option (right to buy)
[F7]Exercise: $97.13Exp: 2028-04-01→ Common Stock (3,856 underlying) - 19,032
Stock Option (right to buy)
[F7]Exercise: $120.46Exp: 2028-08-06→ Common Stock (19,032 underlying) - 24,560
Stock Option (right to buy)
[F8]Exercise: $94.52Exp: 2029-08-15→ Common Stock (24,560 underlying) - 12,649
Stock Option (right to buy)
[F9]Exercise: $84.61Exp: 2030-08-15→ Common Stock (12,649 underlying) - 7,327
Stock Option (right to buy)
[F10]Exercise: $73.46Exp: 2031-05-01→ Common Stock (7,327 underlying) - 17,133
Stock Option (right to buy)
[F11]Exercise: $74.91Exp: 2034-08-15→ Common Stock (17,133 underlying) - 5,434
Stock Option (right to buy)
[F12]Exercise: $48.61Exp: 2035-06-02→ Common Stock (5,434 underlying) - 19,151
Stock Option (right to buy)
[F13]Exercise: $53.60Exp: 2035-08-15→ Common Stock (19,151 underlying) - 2,387
Performance Restricted Stock Units
[F1][F14]→ Common Stock (2,387 underlying) - 735
Restricted Stock Units
[F1][F15]→ Common Stock (735 underlying) - 1,911
Stock Option (right to buy)
[F16]Exercise: $57.82Exp: 2036-03-02→ Common Stock (1,911 underlying)
Footnotes (17)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- [F10]Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027.
- [F11]Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026.
- [F12]Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029.
- [F13]Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028.
- [F14]Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- [F15]245 restricted stock units vest on 3/2/2027, 3/2/2028 and 3/2/2029.
- [F16]Options to purchase 478 shares vest on each of 3/2/2027, 3/2/2028 and 3/2/2030; and options to purchase 477 shares vest on 3/2/2029.
- [F17]Due to a mathematical error on the Form 4 filed May 5, 2026, the number of shares beneficially owned is being increased by 40 shares and this filing represents the correct number of shares beneficially owned by the Reporting Person.
- [F2]794 restricted stock units vest on 5/1/2027.
- [F3]600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028.
- [F4]1,379 restricted stock units vest on 8/15/2026.
- [F5]1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027.
- [F6]2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027.
- [F7]100% vested.
- [F8]Options to purchase 6,140 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
- [F9]Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025.